Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Common Equity: 2018-2024

Historic Common Equity for Revolution Medicines (RVMD) over the last 7 years, with Dec 2024 value amounting to $2.3 billion.

  • Revolution Medicines' Common Equity rose 1.95% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 1.95%. This contributed to the annual value of $2.3 billion for FY2024, which is 24.04% up from last year.
  • Revolution Medicines' Common Equity amounted to $2.3 billion in FY2024, which was up 24.04% from $1.8 billion recorded in FY2023.
  • Over the past 5 years, Revolution Medicines' Common Equity peaked at $2.3 billion during FY2024, and registered a low of $474.7 million during FY2020.
  • Over the past 3 years, Revolution Medicines' median Common Equity value was $1.8 billion (recorded in 2023), while the average stood at $1.6 billion.
  • Data for Revolution Medicines' Common Equity shows a peak YoY spiked of 411.11% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Revolution Medicines' Common Equity stood at $474.7 million in 2020, then increased by 26.94% to $602.6 million in 2021, then climbed by 13.71% to $685.2 million in 2022, then skyrocketed by 166.52% to $1.8 billion in 2023, then rose by 24.04% to $2.3 billion in 2024.